In Vitro Characterization of MAT LyLu: A Dunning Rat Prostate Adenocarcinoma Tumor Subline

Wenger, Allen S.; Mickey, Don D.; Hall, Margot; Silverman, Lawrence M.; Mickey, George H.; Fried, Floyd A.

doi:10.1016/s0022-5347(17)50879-4

Cited by 16 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, two prostate cancer cell lines were used: firstly, human PC3 cells which have high metastatic potential and have been used in advanced prostatic cancer studies [22]. Secondly, a rat line MatLyLu, which has previously been used for syngeneic tumour rat model studies [23], [24].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of photochemical internalisation using disulfonated chlorin and porphyrin photosensitisers: An in vitro study in 2D and 3D prostate cancer models

et al. 2017

View full text Add to dashboard Cite

This study shows the therapeutic outcome of Photochemical Internalisation (PCI) in prostate cancer in vitro surpasses that of Photodynamic Therapy (PDT) and could improve prostate PDT in the clinic, whilst avoiding chemotherapeutics side effects. In addition, the study assesses the potential of PCI with two different photosensitisers (TPCS2a and TPPS2a) in prostate cancer cells (human PC3 and rat MatLyLu) using standard 2D monolayer culture and 3D biomimetic model. Photosensitisers were used alone for photodynamic therapy (PDT) or with the cytotoxin saporin (PCI). TPPS2a and TPCS2a were shown to be located in discrete cytoplasmic vesicles before light treatment and redistribute into the cytosol upon light excitation. PC3 cells exhibit a higher uptake than MatLyLu cells for both photosensitisers. In the 2D model, PCI resulted in greater cell death than PDT alone in both cell lines. In 3D model, morphological changes were also observed. Saporin-based toxicity was negligible in PC3 cells, but pronounced in MatLyLu cells (IC50 = 18 nM). In conclusion, the study showed that tumour features such as tumour cell growth rate or interaction with drugs determine therapeutic conditions for optimal photochemical treatment in metastatic prostate cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of photochemical internalisation using disulfonated chlorin and porphyrin photosensitisers: An in vitro study in 2D and 3D prostate cancer models

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Male Copenhagen rats were obtained from Charles River Laboratories, Inc., and reached maturity (2-3 months) before experimental manipulation. The tumor model, R3327 MAT LyLu is an autonomous, anaplastic, fast-growing, hormoneunresponsive, metastatic tumor [29]. These phenotypic characteristics are likely to be present in human prostate adenocarcinomas chosen for conventional chemotherapy.…”

Section: Animals and Tumor Modelmentioning

confidence: 99%

“…These different sublines parallel the various stages of human prostate carcinoma [22]. The Dunning model has also served as an appropriate model for analysis of various treatment modalities [ 10,11,23-281. The present studies used the subline MAT LyLu [29] to investigate the changes in solid tumor growth rates in host animals during therapy with the differentiation agents alone, conventional agents alone, and in combination.…”

Section: Introductionmentioning

confidence: 99%

Conventional chemotherapeutic agents combined with DMSO or DFMO in treatment of rat prostate carcinoma

Mickey¹,

Carvalho²,

Foulkes³

1989

The Prostate

Self Cite

View full text Add to dashboard Cite

Chemotherapy for prostatic carcinoma is usually reserved for those patients who have failed conventional therapy. These patients generally are in poor health and tolerate chemotherapy poorly. If doses of conventional agents could be decreased without altering cytotoxic activity, then conventional chemotherapy could become an attractive treatment modality. Dimethylsulfoxide and difluoromethylornithine have been shown to induce differentiation in some tumor systems. Growth alteration effects of these two agents were investigated individually and in association with conventional chemotherapeutic agents cyclophosphamide, cisplatin, and fluorouracil in an experimental prostatic cancer model. Copenhagen rats had subcutaneous tumors induced by injections of cells cultured in vitro from a subline of the Dunning rat prostatic tumor, MAT LyLu. Treatment with chemotherapeutic agents individually and associated with differentiation agents was initiated when tumors were palpable. Tumor growth rates and rat body weights were monitored in all groups. The differentiation agents used singly were not able to retard significantly tumor growth rates. In higher doses, each conventional agent used singly significantly retarded tumor growth. Used in combination, the differentiation agents induced cytodestructive properties of lower doses of conventional agents, but some combinations also increased host toxicity. These data suggest that differentiation agents may provide additional antineoplastic benefits when administered in combination with selected chemotherapeutic agents in the management of prostatic cancer.

show abstract

“…At the 60th passage, the R-3327 AT tumor cell line displayed a high metastatic potential and increased growth rate (doubling time of approximately 1.5 days) and was renamed the MAT (metastatic-AT) tumor 27. The new MAT tumor cell line reproducibly resulted in the metastatic development of tumors at the lymph nodes and within the lungs 27,31. As such, the tumor cell line was dubbed the MATLyLu or “metastatic anaplastic tumor capable of spreading to the lymph nodes and lungs” cell line 27.…”

Section: Introductionmentioning

confidence: 99%

Characterization of a rat model of metastatic prostate cancer bone pain

Ciantis¹,

Yashpal²,

Henry³

et al. 2010

JPR

View full text Add to dashboard Cite

Purpose:The objectives of this study were to establish and characterize a novel animal model of metastatic prostate cancer-induced bone pain.Methods:Copenhagen rats were injected with 106 MATLyLu (MLL) prostate cancer cells or phosphate-buffered saline by per cutaneous intra femoral injections into the right hind leg distal epiphysis. Over 13 days, rats progressively developed a tumor within the distal femoral epiphysis. On days 3, 7, 10, and 13 post injection, rats were subjected to the incapacitance and Randall–Selitto behavioral tests as they are believed to be indirect reflections of tumor induced pain. Ipsilateral hind limbs were subjected to X-ray and computed tomography (CT) scans and histological sections were stained with hematoxylin and eosin (H&E).Results:Intra femoral injections of MLL cells resulted in the progressive development of a tumor leading to bone destruction and nociceptive behaviors. Tumor development resulted in the redistribution of weight to the contralateral hind leg and significantly reduced the paw withdrawal threshold of the ipsilateral hind paw as observed via the incapacitance and Randall–Selitto tests, respectively. X-ray and computed tomography scans along with H&E stains indicated tumor-associated structural damage to the distal femur. This model was challenged with administration of meloxicam. Compared with vehicle-injected controls, the meloxicam-treated rats displayed smaller nociceptive responses as observed with the incapacitance and Randall–Selitto tests, suggesting that meloxicam was effective in reducing the pain-related symptoms displayed by model animals and that the model behaved in a predictable way to cyclooxygenase-2 treatment.Conclusions:This model is unique from other bone cancer models in that it is a comprehensive model utilizing a competent immune system with a syngeneic tumor. The model establishes a tool that will be useful to investigate mechanisms of cancer pain that are induced by cancer cells.

show abstract

In Vitro Characterization of MAT LyLu: A Dunning Rat Prostate Adenocarcinoma Tumor Subline

Cited by 16 publications

References 18 publications

Efficacy of photochemical internalisation using disulfonated chlorin and porphyrin photosensitisers: An in vitro study in 2D and 3D prostate cancer models

Efficacy of photochemical internalisation using disulfonated chlorin and porphyrin photosensitisers: An in vitro study in 2D and 3D prostate cancer models

Conventional chemotherapeutic agents combined with DMSO or DFMO in treatment of rat prostate carcinoma

Characterization of a rat model of metastatic prostate cancer bone pain

Contact Info

Product

Resources

About